None of the abovementioned studies reported the proportion of patients with type 1 diabetes (T1D) included. However, type of diabetes may also be of great importance because the long-term prognosis after CABG is dire in patients with T1D (6), compared with patients with type 2 diabetes (T2D) whose longterm prognosis is similar to that of patients without (3, 6) . The reason for the poor prognosis in patients with T1D after CABG is not fully understood;
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however, factors such as diabetes duration and glycemic control may be of great importance (7) . Therefore, the recommendation that all diabetes patients in need of multivessel revascularization should undergo CABG cannot easily be translated to patients with T1D.
Thus, it is unknown whether patients with T1D have the same benefit as patients with T2D from CABG compared with PCI. Therefore, we performed a nationwide, population-based cohort study in all patients with T1D who underwent a first multivessel revascularization with either CABG or PCI over a period of 19 years in Sweden. FOLLOW-UP AND OUTCOMES. The primary outcome was all-cause mortality, and secondary outcomes were death from coronary heart disease, myocardial infarction, stroke, and repeat revascularization. Follow-up started when the first multivessel PCI or CABG was performed for all-cause mortality, and stroke. For repeat revascularization follow-up started at 8 days after revascularization, and for myocardial infarction, and heart failure 31 days after revascularization. Follow-up ended for all outcomes when the patient died, was hospitalized for each outcome, or on December 31, 2014. Data on rehospitalizations for myocardial infarction, heart failure, stroke, or repeat revascularization was obtained from Table 2 Statistical hypothesis tests were evaluated using the 5% significance level without any adjustment for multiple comparisons. The analysis was implemented using R and SAS statistical analysis software, version 9.4 (SAS Institute Inc., Cary, North Carolina).
RESULTS
STUDY GROUP. During the study period, 2,546 patients with T1D underwent a first multivessel revascularization, of which 73% underwent PCI. The selection of the study group is described in Figure 1 .
Patients treated with PCI were older, more often women, had a longer duration of diabetes, and were more likely to have had previous myocardial infarctions and strokes ( MORTALITY. During a mean 10.6 AE 5.1 years (22,386 person-years) of follow-up, 44.6% patients in the PCI group and 53.3% in the CABG group died ( Table 2 ).
The absolute risk of death was higher at 1 year Nyström et al.
The risk of death after adjustment for differences between groups was similar in the PCI group compared to the CABG group (HR: 1.14; 95% CI: 0.99 to 1.32).
Cause-specific mortality showed that patients who underwent PCI were more likely to die from coronary heart disease than were patients who underwent CABG (HR: 1.45; 95% CI: 1.21 to 1.74) (Table 2, Figure 2A ).
MYOCARDIAL INFARCTION, HEART FAILURE, STROKE, AND REPEAT REVASCULARIZATION. The absolute risks at 1 year, 2 years, and 5 years after revascularization for myocardial infarction, heart failure, stroke, and repeat revascularizations were consistently higher in patients who underwent PCI compared with those who underwent CABG, with the largest difference found for repeat revascularizations ( Table 3, Figures 2B to 2E). The rate and adjusted risk of myocardial infarction in the PCI group was higher than in the CABG group (4.6/100 person-years vs. 2.7/100 person-years; adjusted HR: 1.47; 95% CI: 1.21 to 1.77) ( Table 2) . Similarly, the adjusted risk for and the frequency of repeat revascularization was higher in the PCI group than in the CABG group (20.1/100 person-years vs. 1.9/100 person-years; adjusted HR: 5.64; 95% CI: 4.67 to 6.82).
Repeat revascularization was performed using CABG in 64% of the cases in the PCI group, compared with 1% This figure shows how the study population, which included patients with type 1 diabetes (T1D) and multivessel disease who underwent either percutaneous coronary intervention (PCI) (n ¼ 1,863), or coronary artery bypass grafting (CABG) (n ¼ 683) in Sweden from 1995 to 2013, was selected, and how many patients were excluded and for what reason at each step. STEMI ¼ ST-segment elevation myocardial infarction.
in the CABG group. The 30-day rate of stroke was higher in the CABG group than in the PCI group (1.9% vs. 0.8%), but there was no difference in the long-term adjusted risk of stroke between the PCI and CABG groups. The adjusted risk of hospitalization for heart failure was similar in the PCI and CABG groups.
DISCUSSION
In this nationwide cohort study including all patients with T1D who underwent a first multivessel revascularization in Sweden from 1995 to 2013, we found a benefit favoring CABG over PCI, with lower rates and risks of coronary heart disease mortality, myocardial infarction, and repeat revascularization, with no such differences found for all-cause mortality, stroke, and heart failure.
Earlier studies have provided evidence of a benefit for CABG compared with PCI in terms of prognosis in patients with diabetes in need of multivessel revascularization (1-3,11) . The strongest evidence for using CABG over PCI as the preferred strategy for multivessel revascularization in patients with diabetes comes from the FREEDOM study (2); however, none of the previously mentioned studies reported the proportion of included T1D compared with T2D patients. Because 85% to 90% of all patients with diabetes have T2D (12) , it is likely that the proportion of T1D patients included was very small. To the best of our knowledge, only 1 previous study that compared PCI with CABG for multivessel revascularization in patients with diabetes sorted patients into T1D and T2D subgroups (13) . This study was prematurely stopped due to slow enrollment, comprising a total of 510 diabetes patients, of whom only 5% had T1D. Due to the small number of T1D patients involved, no interpretation could be drawn from this group. As patients with T1D have a significantly increased long-term risk of death after CABG compared with patients with T2D (6), and patients without diabetes and with T2D have a similar long-term risk of death after CABG (2,6), there is a Values are number of events (%). *Follow-up started 31 days after revascularization for MI and HF failure hospitalization. †Follow-up started 8 days after the index revascularization.
Abbreviations as in Tables 1 and 2 . Follow-up started at the time of revascularization for death, stroke, and death from coronary heart disease. For MI and heart failure (HF), follow-up started 31 days after revascularization, and follow-up for repeat revascularization started 8 days after revascularization.
CHD ¼ coronary heart disease; CI ¼ confidence interval; HR ¼ hazard ratio; T1D ¼ type 1 diabetes; other abbreviations as in Table 1 .
Nyström et al.
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In the present study, we found increased coronary heart disease mortality in the PCI group. This finding was first reported in the BARI study, which enrolled patients between 1988 and 1991 (1). Similarly, patients treated with PCI in the FREEDOM study (2), which was conducted more than 10 years after the BARI study (1) , had increased all-cause mortality.
Similar to the findings in our study, in the subgroup analyses of patients with diabetes in the SYNTAX study, there was a trend towards an increased all-cause mortality, and a significantly increased cardiac-specific mortality in patients who underwent PCI compared to those who underwent CABG (2). We found the largest differences in risk between CABGand PCI-treated patients for myocardial infarction and repeat revascularization. In the FREEDOM study, a similar association was found, with more than double the rate of myocardial infarction in the PCI group 5 years after randomization (2).
The FREEDOM study, which included patients between 2005 and 2010, reported 5-year event rates similar to those in our study for all outcomes, except for a higher rate of death. This may partly be related to an older study population included in the FREEDOM study (2) . In the current study, the 30-day risk of stroke was higher in the CABG group, with event rates similar to those in the FREEDOM study, but the absolute risk was small, and the difference between patients treated with PCI and those treated with CABG had disappeared after 2 years of follow-up. Furthermore, in the BARI 2D study, patients with T2D were randomized to medical treatment or revascularization in 2 groups: one where patients were treated with PCI, and the other where they were treated with CABG (14 This figure shows the cumulative incidence, estimated with the Kaplan-Meier method, of (A) coronary heart disease (CHD) mortality, (B) acute myocardial infarction (AMI), (C) heart failure (HF), (D) stroke, and (E) repeat revascularization during follow-up in T1D patients treated with PCI or CABG. Follow-up started at the time of revascularization for death and stroke, at 31 days after the intervention for myocardial infarction and heart failure, and 8 days after the intervention for repeat revascularization. Abbreviations as in Figure 1 . Therefore, the target vessel for a bypass graft in patients with diabetes is often in an inferior condition compared with the target vessel from patients without diabetes. Despite this, cardiovascular complications differ between T1D and T2D, not only in that T1D presents at younger age, but also in that women are affected to the same degree and at the same age as men (7) . Also, poor glycemic control before CABG is associated with increased risk of death in patients with T1D (17) , an association that is not as pronounced in patients with T2D (18) . Previous studies have demonstrated that both glycemic control and insulin treatment are predictors of long-term outcomes after CABG (19) (20) (21) . Recently, it was demonstrated, in a substudy of the FREEDOM study, that the clinical event rate was higher in patients with diabetes treated with insulin compared to those without insulin treatment; however, no interaction was demonstrated between groups, suggesting that insulin treatment in itself is not a risk factor for the prognosis in patients with diabetes undergoing PCI or CABG (22) . In the current study, patients who underwent PCI were older, were more often female, had a longer duration of diabetes, lower GFR, and were more likely to have heart failure, active cancer, endstage renal disease, and prior stroke compared with patients who underwent CABG. After adjustment for these and a number of other differences, there was still an excess risk and rate of coronary heart disease mortality, myocardial infarction, and repeat revascularization in patients with T1D who underwent PCI compared with those who underwent CABG.
Based on data from the BARI study, the National The reason why guideline recommendations were not followed, and PCI was chosen over CABG to such a large extent in our observational study, remains elusive. However, by using inverse probability of treatment weighting based on propensity scores, we adjusted for these differences, but cannot exclude that there was residual confounding present, even after adjustment. We had no information about cardiovascular medications aimed at secondary prevention.
This most likely diluted the finding of an increased risk associated with PCI treatment compared with CABG treatment because secondary prevention became more aggressive during the study period, specifically in diabetes patients. Moreover, we had no information on the types of stents used, which varied between bare-metal stents and different types of drug-eluting stents due to the long study period.
However, in previous studies, the benefit of CABG over PCI in patients with diabetes has been independent of whether bare-metal stents (1), or drug-eluting stents (2,3) have been used. Another limitation was that we were not able to adjust for changes in the epidemiology of coronary heart disease, with a significantly reduced incidence of myocardial infarction and reduced long-term mortality following myocardial infarction during the
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Revascularization in Patients With Type 1 Diabetes study period (24) . As CABG was the preferred method for multivessel revascularization during the early years of the study period, with higher risks associated with coronary heart disease, we believe that this may have, if anything, diluted our findings. The largest differences in risk were found for repeat revascularization, and myocardial infarction, which is related to the completeness of revascularization among PCI patients (25) . These differences may have been attenuated if we would have been able to adjust for complete or incomplete revascularization in the PCI group (25). As our study was an observational cohort study, the results may not be completely comparable to the findings in the BARI, FREEDOM, or SYNTAX studies, where patients with diabetes were randomized to treatment with either PCI or CABG (1-3).
The main strength of our study was the size of this unique study population of T1D patients and the large number of events, with 1,195 deaths, and 726 myocardial infarctions during a mean follow-up of more than 10 years. This allowed us to report risks for each outcome separately, and with high precision in our estimates. We used high-quality national health care registers to obtain information, all of which were previously evaluated and found to have high validity (8) (9) (10) . The Patient and the Cause-of-Death register used to retrieve outcomes has complete coverage of the country, and therefore we had no loss to follow-up.
CONCLUSIONS
Notwithstanding the inclusion of patients who might not have been able to undergo CABG in the PCI group, in this nationwide cohort of T1D patients with multivessel coronary artery disease, we found that CABG was associated with a lower risk of coronary heart disease mortality, myocardial infarction, and repeat revascularization compared with PCI.
Even if our findings indicate that CABG should be the preferred strategy for multivessel revascularization in patients with T1D, our findings should be interpreted with some caution because of the observational nature of the study, and maybe more importantly, the large differences in risks in the first year of follow-up, indicating that there were large inherent differences in risk at baseline between the PCI and CABG groups. Revascularization in Patients With Type 1 Diabetes S E P T E M B E R 1 9 , 2 0 1 7 : 1 4 4 1 -5 1
